KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitIncome Before Income TaxesInventoriesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Costs & ExpensesOpex & Costs As A % Of RevenueProperty, Plant And Equipment, Net By Geography AnnualProperty, Plant & Equipment (Gross)Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By Major Customers AnnualRevenue By Major Customers Annual %Revenue By ProductRevenue By Product AnnualRevenue By Product Annual %Revenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By Therapeutic AreaRevenue By Therapeutic Area Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Gross Profit (2016 - 2025)

Gilead Sciences filings provide 17 years of Gross Profit readings, the most recent being $6.3 billion for Q4 2025.

  • On a quarterly basis, Gross Profit rose 5.23% to $6.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $23.2 billion, a 3.14% increase, with the full-year FY2025 number at $23.2 billion, up 3.14% from a year prior.
  • Gross Profit hit $6.3 billion in Q4 2025 for Gilead Sciences, up from $6.2 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $6.3 billion in Q4 2025 to a low of $4.6 billion in Q4 2021.
  • Median Gross Profit over the past 5 years was $5.3 billion (2022), compared with a mean of $5.4 billion.
  • Biggest five-year swings in Gross Profit: decreased 23.34% in 2021 and later rose 29.8% in 2022.
  • Gilead Sciences' Gross Profit stood at $4.6 billion in 2021, then grew by 29.8% to $6.0 billion in 2022, then dropped by 16.17% to $5.0 billion in 2023, then increased by 19.19% to $6.0 billion in 2024, then increased by 5.23% to $6.3 billion in 2025.
  • The last three reported values for Gross Profit were $6.3 billion (Q4 2025), $6.2 billion (Q3 2025), and $5.6 billion (Q2 2025) per Business Quant data.